Research programme: drug discovery - AMRI/Bristol-Myers Squibb

Drug Profile

Research programme: drug discovery - AMRI/Bristol-Myers Squibb

Alternative Names: Natural products-based drugs

Latest Information Update: 09 Feb 2009

Price : $50

At a glance

  • Originator Albany Molecular Research; Bristol-Myers Squibb
  • Developer AMRI; Bristol-Myers Squibb
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 31 Dec 2008 Discontinued - Preclinical for Undefined indication in USA (unspecified route)
  • 22 Dec 2008 AMRI and Bristol-Myers Squibb conclude their two-year collaboration on the discovery of natural products-based drugs for various Undefined indications
  • 02 May 2007 Albany Molecular Research is now called AMRI
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top